Managing Abnormal Pap Smears
Transcript of Managing Abnormal Pap Smears
![Page 1: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/1.jpg)
ASHLYN SAVAGE, MD, MSCR A S S O C I A T E P R O F E S S O R
O B S T E T R I C S A N D G Y N E C O L O G Y M E D I C A L U N I V E R S I T Y O F S O U T H C A R O L I N A
Managing Abnormal Pap Smears: Incorporating biomarkers and new guidelines
into your practice
![Page 2: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/2.jpg)
Disclosures
None
![Page 3: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/3.jpg)
Objectives
Participant should be able to:
Use p16 testing
Access and apply new ASCCP guidelines for the management of abnormal cytology and cervical cancer precursors
![Page 4: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/4.jpg)
What has changed…
The way we screen for cervical disease
The way we talk about histology
The way we triage “mid-grade” histology
The way we manage and follow abnormal cytology
….SO, PRETTY MUCH EVERYTHING
![Page 5: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/5.jpg)
Histopathology Terminology: LAST Project
Bethesda (2001) standardized cytology reporting
No such standardized system for histology reporting Confusion over biological equivalents can lead to over-treatment
Many practitioners were already using a two-tiered system due to difficulties with diagnosis of CIN 2
Lower Anogenital Tract Squamous Terminology Project - 2012 Consensus conference CAP and ASCCP
![Page 6: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/6.jpg)
LAST Recommendations
Unified, 2-tiered histopath nomenclature for all HPV-associated pre-invasive squamous lesions of the LAT
LSIL or HSIL
Further classification using “-IN” terminology is appropriate
This distinguishes site (CIN, cervical; VIN, vulvar)
Can also separate grades (-IN 2 vs. –IN 3)
![Page 7: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/7.jpg)
P16 Biomarker
p16
Biomarker, tested via immunohistochemistry
Presence reflects activation HPV oncogene-driven cell proliferation
Image from incyte diagnostics
![Page 8: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/8.jpg)
Indications and Utility of p16 Testing
Distinguishing true pre-cancer from: Mimics such as immature metaplasia, atrophy
Low grade disease
Adjudication tool for inter-observer differences in interpretation
Evaluating cytologic and histologic discrepancies Cytology of HSIL, ASC-H, AGC, or ASCUS/ HPV 16+ and histology
interpreted as normal or LSIL
**Not intended for use in “clear” cases of –IN 1 or –IN 3
![Page 9: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/9.jpg)
New Format of Results
Cervical Biopsy Results following an ASC-H pap smear
SURG PATH FINAL REPORT:
*** ADDENDUM PRESENT *** Addendum Discussion A. CERVIX, LABELED AS "7 O'CLOCK", BIOPSY: HIGH GRADE INTRAEPITHELIAL LESION, (CIN II, MODERATE DYSPLASIA) IMMUNOHISTOCHEMICAL STAIN RESULT: p16: POSITIVE
B. CERVIX, LABELED AS "1 O'CLOCK", BIOPSY: HIGH GRADE INTRAEPITHELIAL LESION, (CIN II, MODERATE DYSPLASIA) WITH SUPERFICIAL ENDOCERVICAL GLAND INVOLVEMENT IMMUNOHISTOCHEMICAL STAIN RESULT: p16: POSITIVE
![Page 10: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/10.jpg)
New Guidelines for Managing Abnormal Cytology
Massad LS et al. Obstet Gynecol, April 2013
![Page 11: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/11.jpg)
Why new guidelines?
Reflect new screening recommendations Handling results of co-testing
Return to “routine screening” when intervals are longer
New data, esp regarding management of high grade abnormalities Kaiser, 1.4 million women, 8 years of follow up
More extensive incorporation of HPV testing
Guidelines for women under 21 no longer applicable
Katki, HA J Low Gen Tract Dis, April 2013
![Page 12: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/12.jpg)
Guiding Principles
Equal management for women at equal risk
Diagnoses with similar risks should be managed similarly
Guidelines based upon currently available data
Screening goal is to reduce, but not eliminate, risk of cervical cancer
Guidelines do not trump clinical judgment
![Page 13: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/13.jpg)
Benchmarking
Katki, HA J Low Gen Tract Dis, April 2013
![Page 14: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/14.jpg)
Equal Management for Equal Risk
5 year risk of Cin 3
>5% Immediate colposcopy
2-5% Repeat testing in 6-12 months
0.1-2% Repeat testing in 3 years
<0.1% Repeat testing in 5 years
![Page 15: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/15.jpg)
The Young Patient
21 year old with first pap ever = ASCUS or LSIL
HPV Testing
![Page 16: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/16.jpg)
60% of ASCUS
are HPV +
![Page 17: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/17.jpg)
HSIL in the Young Patient
Note: Observation is colpo and cytology q 6
mos
![Page 18: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/18.jpg)
Co-Testing Dilemmas
Cytology negative, HPV positive
• 4 % of women undergoing co-testing will have this result
• 5 year risk of CIN 3+ was 4.5%
Cumulative risk of disease in women at 30-64 with baseline negative cytology / HPV +
Katki, HA et al. J Low Genit Tract Dis, April 2013
![Page 19: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/19.jpg)
Co-testing Dilemmas
![Page 20: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/20.jpg)
Co-testing Dilemmas
Pap LSIL,
HPV negative
• 12-30% of LSIL are HPV negative
Pap neg = 0.26
Katki, HA J Low Gen Tract Dis, April 2013
![Page 21: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/21.jpg)
Co-testing Dilemmas
![Page 22: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/22.jpg)
Disease Surveillance: Getting back to “routine” screening
Antecedent pap affects long term risk of high grade disease
Katki, HA J Low Gen Tract Dis, April 2013
![Page 23: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/23.jpg)
Follow Up After Colpo Dx of Normal or CIN 1
Antecedent ASCUS/HPV+ or LSIL Antecedent ASC-H, HSIL, AGC
Katki, HA J Low Gen Tract Dis, April 2013
![Page 24: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/24.jpg)
![Page 25: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/25.jpg)
![Page 26: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/26.jpg)
Post Treatment Follow UP
![Page 27: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/27.jpg)
ASCUS/ HPV negative: “Normal”, or Not?
Katki, HA J Low Gen Tract Dis, April 2013
![Page 28: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/28.jpg)
ASCUS / HPV Negative
![Page 29: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/29.jpg)
Exiting Screening
Katki, HA J Low Gen Tract Dis, April 2013
![Page 30: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/30.jpg)
Exiting From Screening
Postmenopausal women with ASC-US should be managed in the same manner as women in the general population
Except when considering exit from screening: Women aged 65 years and older with HPV-negative ASC-US
should have repeat co-testing in one year
![Page 31: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/31.jpg)
![Page 32: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/32.jpg)
![Page 33: Managing Abnormal Pap Smears](https://reader031.fdocuments.net/reader031/viewer/2022012418/61736fec3ca4d7593366beb7/html5/thumbnails/33.jpg)
Thank You